Cytokinetics Inc (CYTK)
Cash conversion cycle
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Days of inventory on hand (DOH) | days | — | — | — | — | — |
Days of sales outstanding (DSO) | days | — | — | — | — | — |
Number of days of payables | days | — | — | — | — | — |
Cash conversion cycle | days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= — + — – —
= 0.00
Based on the provided data, Cytokinetics Inc's cash conversion cycle has been consistently reported as 0.00 days from December 31, 2020, through December 31, 2024. This indicates that the company is efficiently managing its cash flow, as it takes zero days for Cytokinetics to convert its investments in inventory and receivables into cash from sales. A shorter cash conversion cycle is generally a positive sign, as it implies that the company is able to quickly convert its assets into cash, which can help improve liquidity and overall financial health.
Peer comparison
Dec 31, 2024
Company name
Symbol
Cash conversion cycle
Cytokinetics Inc
CYTK
0.00
Abbott Laboratories
ABT
120.86
AbbVie Inc
ABBV
90.28
ACADIA Pharmaceuticals Inc
ACAD
97.89
Alkermes Plc
ALKS
146.34
Amphastar P
AMPH
193.56
ANI Pharmaceuticals Inc
ANIP
199.53
Arcus Biosciences Inc
RCUS
-36.73
Biomarin Pharmaceutical Inc
BMRN
860.14
Bristol-Myers Squibb Company
BMY
69.21
Catalyst Pharmaceuticals Inc
CPRX
103.60